HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamagishi, H. Articles by Utsunomiya, Y. Search for Related Content PubMed PubMed Citation Articles by Yamagishi, H. Articles by Utsunomiya, Y.

Genetically Modified Bone Marrow-Derived Vehicle Cells Site Specifically Deliver an Anti-Inflammatory Cytokine to Inflamed Interstitium of Obstructive Nephropathy¹

Hiroko Yamagishi^*, Takashi Yokoo^*,, Toshiyuki Imasawa^*, Tetsuya Mitarai, Tetsuya Kawamura^* and Yasunori Utsunomiya^2,*

^* Department of Internal Medicine, Division of Nephrology and Hypertension, and Department of Gene Therapy, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan; and Department of Internal Medicine, Saitama Medical School, Kawagoe, Saitama, Japan

In this study, we used genetically modified bone marrow-derived CD11b⁺CD18⁺ vehicle cells to deliver IL-1 receptor antagonist (IL-1ra) for treatment of inflamed renal interstitium in an animal model of unilateral ureteral obstruction (UUO). Vehicle cells that expressed the ICAM-1 ligands, CD11b and CD18, were obtained from bone marrow cells of DBA/2j mice and adenovirally transduced with the IL-1ra gene or glucocerebrosidase (GC) gene ex vivo. In kidneys treated to develop UUO, levels of ICAM-1, IL-1, and IL-1R expression increased within 3 days compared with contralateral untreated kidneys in the same mice. Similarly, the macrophage infiltration in the cortical interstitium increased after 3 days in UUO kidneys, but not untreated kidneys. After UUO developed, DBA/2j mice were injected i.v. with either IL-1ra⁺ vehicle cells (IL-1ra-treated mice) or GC⁺ vehicle cells (GC-treated mice) at 24 h after UUO. Six days after the injection of these vehicle cells, marked increase of CD11b⁺ IL-1ra⁺ vehicle cells was observed in the ICAM-1-positive interstitium of UUO kidneys from IL-1ra-treated mice. In contrast, no CD11b⁺ IL-1ra⁺ cells appeared in ICAM-1-negative contralateral kidneys from these mice. Furthermore, the infiltration of macrophages (p < 0.001), expression of ICAM-1 (p < 0.005), and presence of -smooth muscle actin (p = 0.005) in the interstitium of UUO kidneys were significantly decreased in IL-1ra-treated mice compared with GC-treated mice. These findings suggest that IL-1 may contribute to the development of renal interstitial injury and that our method can deliver a functioning gene encoding an antiinflammatory cytokine gene specifically at that site by interacting with local adhesion molecules.

This article has been cited by other articles:

				P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]

				N. G. Docherty, O. E. O'Sullivan, D. A. Healy, J. M. Fitzpatrick, and R. W. G. Watson Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction Am J Physiol Renal Physiol, January 1, 2006; 290(1): F4 - F13. [Abstract] [Full Text] [PDF]

				L.-P. Erwig, D. C. Kluth, and A. J. Rees Macrophage heterogeneity in renal inflammation Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1962 - 1965. [Full Text] [PDF]

				S. Klahr and J. Morrissey Obstructive nephropathy and renal fibrosis Am J Physiol Renal Physiol, November 1, 2002; 283(5): F861 - F875. [Abstract] [Full Text] [PDF]